Latest Conference Articles

The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.

JDQ443 Demonstrates Early Efficacy Signals in KRAS G12C-Mutant Solid Tumors

April 11th 2022, 11:18pm

AACR Annual Meeting

The novel KRAS G12C inhibitor, JDQ443, demonstrated early efficacy signals and a tolerable safety profile in initial data from the dose-escalation portion of the phase 1b/2 KontRASt-01 trial.

Combined Immune Pathway Inhibition Improves Responses in Resectable NSCLC

April 11th 2022, 9:25pm

Durvalumab plus either oleclumab, monalizumab, or damvatirsen led to an improvement in major pathologic response vs durvalumab alone as neoadjuvant therapy in patients with resectable, early-stage non–small cell lung cancer, according to findings from the phase 2 NeoCOAST clinical trial.

Nivolumab Plus Chemotherapy Improves Event-Free Survival in Resectable NSCLC

April 11th 2022, 8:45pm

The combination of nivolumab plus platinum-doublet chemotherapy led to a significant improvement in event-free survival compared with chemotherapy alone as neoadjuvant treatment in patients with resectable non–small cell lung cancer, according to findings from the phase 3 CheckMate 816 trial.

Pembrolizumab Plus Chemotherapy Elicits Meaningful pCR for Gastric, GEJ Adenocarcinoma

April 11th 2022, 8:15pm

AACR Annual Meeting

Perioperative pembrolizumab plus standard of care chemotherapy followed by adjuvant pembrolizumab showed a meaningful pathological complete response rate in patients with resectable gastric and gastroesophageal junction adenocarcinoma.

YAP1, Inflamed T-Cell Subtypes Linked With Improved Durvalumab/ Chemo Responses in ES-SCLC

April 11th 2022, 5:25pm

Patients with extensive-stage small cell lung cancer whose disease harbors inflamed or YAP1 molecular subtypes may be more likely to derive superior overall survival benefit from durvalumab and chemotherapy vs those with other overexpressed biomarkers.

Nivolumab/Chemotherapy Generate Survival Benefit Vs Chemotherapy Alone in Gastric Cancer, Regardless of TMB

April 11th 2022, 3:41pm

AACR Annual Meeting

The combination of nivolumab with chemotherapy elicited a higher overall survival rate compared with chemotherapy alone in patients with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma, regardless of tumor mutational burden (TMB) status.

Nivolumab/Ipilimumab Produces Promising ORR in Advanced tTMB- and bTMB-High Solid Tumors

April 11th 2022, 1:05am

AACR Annual Meeting

The dual immunotherapy combination of nivolumab and ipilimumab elicited encouraging and durable responses with acceptable safety in patients with advanced or metastatic tumor mutational burden–high solid tumors that were refractory to standard therapies, meeting the primary end points of the phase 2 CheckMate-848 trial.

Elimusertib Elicits Responses in Solid Tumors With ATM Alterations and BRCA Mutations

April 11th 2022, 12:40am

AACR Annual Meeting

The oral ataxia-telangiectasia and Rad3–related protein inhibitor elimusertib produced durable and prolonged responses in patients with advanced solid tumors who have ATM gene alterations and BRCA1/2 defects.

Olaparib Combination Shows Notable Non-Progression Rate in Endometrial Cancer

April 11th 2022, 12:01am

AACR Annual Meeting

In the ENDOLA trial, olaparib in combination with metronomic cyclophosphamide and metformin showed a significant non-progression rate in patients with recurrent advanced or metastatic endometrial cancer.

T-Cell Attributes of Axi-cel Linked to Outcomes in LBCL

April 10th 2022, 11:49pm

AACR Annual Meeting

The T-cell attributes of axicabtagene ciloleucel impacted tumor burden, efficacy outcomes, peak levels of proinflammatory cytokines, and toxicities such as neurologic events and cytokine release syndrome in patients with relapsed/refractory large B-cell lymphoma.

GD2-Directed CAR T-Cell Therapy Elicits Durable Benefit in H3K27M-Mutated Diffuse Intrinsic Pontine Gliomas

April 10th 2022, 9:40pm

AACR Annual Meeting

GD2-directed CAR T-cell therapy demonstrated prolonged periods of radiographic and clinical improvement in pediatric and young adult patients with H3K27M-mutated diffuse intrinsic pontine gliomas and spinal diffuse midline gliomas.

Dr. Dy on the Use of Sotorasib in KRAS G12C–Mutated NSCLC

April 10th 2022, 9:09pm

Grace Dy, MD, discusses the use of sotorasib in patients with non–small cell lung cancer with KRAS G12C mutations.

Off-the-Shelf Anti-Mesothelin CAR T-cell Therapy Improves In Vivo Activity Vs Gavo-Cel in Mesothelin-Expressing Tumors

April 10th 2022, 8:47pm

AACR Annual Meeting

Off-the-shelf anti-mesothelin T-cell receptor fusion construct T cells demonstrated prolonged persistence and efficacy in vivo against mesothelin-expressing tumors in mice, compared with gavocabtagene autoleucel.

Sotorasib Shows Impressive 2-Year OS Rate in KRAS G12C+ NSCLC

April 10th 2022, 8:39pm

AACR Annual Meeting

Sotorasib demonstrated an overall survival rate of 32.5% at 2 years in patients with KRAS G12C–mutant non–small cell lung cancer, according to longer follow-up data from the phase 1/2 CodeBreaK 100 trial.

Biomarker-Directed Therapy Could Lead to Undertreatment of Nonclonal Recurrent DCIS

April 10th 2022, 8:26pm

AACR Annual Meeting

Among patients with ductal carcinoma in situ, a significant portion of recurrences were not genetically related to the primary tumor.

NK Cells Plus Bispecific Antibody Delivers Strong Results in Advanced Lymphoma

April 10th 2022, 7:58pm

AACR Annual Meeting

The innate cell engager AMF13 combined with preactivated and expanded natural killer (NK) cells induced “very encouraging activity” in patients with heavily pretreated lymphoma.

Pembrolizumab Maintains Survival Benefits in 4-year Follow-Up of KEYNOTE-042 in NSCLC in China

April 8th 2022, 10:12pm

First-line pembrolizumab monotherapy continued to elicit an overall survival benefit and durable tumor response vs standard-of-care platinum-based chemotherapy in Chinese patients with untreated PD-L1–positive, advanced or metastatic non–small cell lung cancer without sensitizing EGFR or ALK mutations.

Temferon Displays Activity in Glioblastoma

April 8th 2022, 9:10pm

AACR Annual Meeting

Temferon, genetically modified Tie2-expressing monocytes targeting interferona2, showed the potential to activate the immune system and reprogram the tumor microenvironment in patients with glioblastoma.

Patient Goals and Characteristics Play an Outsized Role in Determining First-Line Treatment for mCRC

April 6th 2022, 4:00pm

Selecting the optimal frontline treatment regimen for patients with unresectable metastatic colorectal cancer requires careful consideration of multiple patient and treatment characteristics.

Biomarkers Continue to Play a Pivotal Role in Treatment Decisions in Metastatic CRC

April 1st 2022, 6:45pm

The expansion of the treatment armamentarium has emphasized the importance of genetic testing in patients with metastatic colorectal cancer, according to Christopher Lieu, MD, who added continued developments in the field have produced additional treatment regimens across patient subsets.